TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01792661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced MyChart
Description: Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator
Description: The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator
Description: The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyChart
Description: Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyChart
Description: Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
Study: NCT02133326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caldolor
Description: Subject will be given Caldolor by IV prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofirmev
Description: Subject will be given Ofirmev prior to surgery.
Study: NCT04071457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Commercially available intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Commercially available intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Commercially available intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Commercially available intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: SWOG-Held IND

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab/rHuPH20
Description: SWOG-Held IND
Study: NCT04846049

Intervention type: OTHER
Intervention: Comprehensive Care
Description: 1. Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~2. Care Planning with Interdisciplinary Team~3. Care coordination~4. Co-management with Primary care~5. Social work needs assessment~6. Patient-centered telehealth using phone, home telehealth, patient portal, Video~7. Transportation provided for all visits~8. Referral to Geriatric primary care clinic and mental health per Veteran need~9. Goals of Care and Veteran preferences conversation~10. Educate primary care providers about HNHR population, home and community based services, collaboration
Study: NCT02930434

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Administration of vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Administration of vitamin D3
Study: NCT04846049

Intervention type: OTHER
Intervention: Standard Care
Description: No intervention or treatment will be provided.
Study: NCT00403923

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lactose in water
Study: NCT00820183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement plan for Hypertension Control
Description: Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation
Study: NCT04461431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic anatomical reconstruction of the posterolateral structure of the knee
Description: Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
Study: NCT02682173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MR Abdomen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MR Abdomen
Study: NCT01888978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-OX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-5FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-Tax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ox-Tax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tax-Iri
Study: NCT01491737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Chemotherapy
Description: Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
Study: NCT04203758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal products based on rye
Description: Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal products based on wheat
Description: Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
Study: NCT05359341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 50 mg
Description: Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 12.5 MG
Description: Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 50 mg + Empagliflozin 12.5 MG
Description: Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 12.5 MG + Sitagliptin 50 mg
Description: Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
Study: NCT01273584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
Study: NCT03334500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace
Description: Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
Study: NCT01220128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A
Description: 6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A
Description: 6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A
Description: 6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A
Description: 6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
Study: NCT01220128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aromatase inhibitor
Description: This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
Study: NCT03334500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace
Description: Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly(ADP Ribose) Polymerase 1
Description: Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly(ADP Ribose) Polymerase 1
Description: Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly(ADP Ribose) Polymerase 1
Description: Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
Study: NCT01220128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT02415816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Magnetic Resonance Imaging
Description: Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
Study: NCT02028663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420
Description: Once daily, Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420
Description: Once daily, Oral administration
Study: NCT03957174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine
Description: Single dose used to increase central norepinepherine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Single dose to increase central acetylcholine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single dose as control condition
Study: NCT01220128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Description: Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
Study: NCT01022034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacral rectopexy with sutures or meshes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: full rectal mobilization from the sacrum without sacral rectopexy
Study: NCT02697019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Emotion Regulation Individual Therapy for Adolescents
Study: NCT01805297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept Injection
Description: One time 2.0mg aflibercept injection, following pars plana vitrectomy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vitrectomy
Description: Surgical intervention
Study: NCT02610140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
Study: NCT02589119

Intervention type: DRUG
Group type: OTHER
Intervention: MSC-AFP
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
Study: NCT01110291

Intervention type: DRUG
Intervention: docetaxel + CEF
Description: Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times.
Study: NCT04536896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone breastfeeding application
Description: This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional face-to-face breastfeeding lecture
Description: This intervention consists of the impartition of a face-to-face breastfeeding course
Study: NCT02928692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02028663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420
Description: Once daily, Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Once daily, Oral administration
Study: NCT00610428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Staccato Placebo
Description: Inhaled Staccato Placebo
Study: NCT00887341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
Study: NCT01336127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
Study: NCT02617589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy